Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study
Abstract Background Hepatitis C virus (HCV) infection prevalence is particularly high in people who inject drugs (PWID), a population that faces many barriers to HCV testing and care. A better understanding of the determinants of access to HCV testing is needed to improve their engagement in the HCV...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | Harm Reduction Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12954-023-00841-7 |
| _version_ | 1797577155881730048 |
|---|---|
| author | Ilhame Anwar Cécile Donadille Camelia Protopopescu David Michels Joris Herin Adélaïde Pladys Danièle Bader Patrizia Carrieri Perrine Roux |
| author_facet | Ilhame Anwar Cécile Donadille Camelia Protopopescu David Michels Joris Herin Adélaïde Pladys Danièle Bader Patrizia Carrieri Perrine Roux |
| author_sort | Ilhame Anwar |
| collection | DOAJ |
| description | Abstract Background Hepatitis C virus (HCV) infection prevalence is particularly high in people who inject drugs (PWID), a population that faces many barriers to HCV testing and care. A better understanding of the determinants of access to HCV testing is needed to improve their engagement in the HCV care cascade. We used data from a cross-sectional survey of people who inject drugs, mainly opioids, to identify factors associated with recent HCV testing. Methods Self-reported data on HCV antibody testing were analyzed for 550 of the 557 PWID enrolled in PrebupIV, a French cross-sectional community-based survey which assessed PWID acceptability of injectable buprenorphine as a treatment. Factors associated with recent (i.e., in the previous six months) HCV antibody testing were identified performing multivariable logistic regression. Results Among the study sample, 79% were men and 31% reported recent HCV antibody testing. Multivariable analysis found that PWID who did not disclose their injection practices to anyone (aOR [95% CI] 0.31 [0.12,0.82], p = 0.018), older PWID (aOR [95% CI] 0.97 [0.95,1.00], p = 0.030) and employed respondents (aOR [95% CI] 0.58 [0.37,0.92], p = 0.019) were all less likely to report recent HCV testing. No association was found between opioid agonist therapy and HCV testing. Conclusions Our findings suggest that non-disclosure of injection practices, employment and age were all barriers to HCV antibody testing. Preventing stigma around injection practices, developing the HCV testing offer in primary care and addiction care services, and training healthcare providers in HCV care management could improve HCV testing and therefore, the HCV care cascade in PWID. |
| first_indexed | 2024-03-10T22:04:00Z |
| format | Article |
| id | doaj.art-1ea56a00585d46778971a05e0e040c73 |
| institution | Directory Open Access Journal |
| issn | 1477-7517 |
| language | English |
| last_indexed | 2024-03-10T22:04:00Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Harm Reduction Journal |
| spelling | doaj.art-1ea56a00585d46778971a05e0e040c732023-11-19T12:50:28ZengBMCHarm Reduction Journal1477-75172023-07-012011910.1186/s12954-023-00841-7Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research studyIlhame Anwar0Cécile Donadille1Camelia Protopopescu2David Michels3Joris Herin4Adélaïde Pladys5Danièle Bader6Patrizia Carrieri7Perrine Roux8Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l’Information Médicale, ISSPAMAix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l’Information Médicale, ISSPAMAix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l’Information Médicale, ISSPAMAIDESBus 31/32Coordination Nationale des Réseaux de Microstructures (CNRMS)Coordination Nationale des Réseaux de Microstructures (CNRMS)Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l’Information Médicale, ISSPAMAix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l’Information Médicale, ISSPAMAbstract Background Hepatitis C virus (HCV) infection prevalence is particularly high in people who inject drugs (PWID), a population that faces many barriers to HCV testing and care. A better understanding of the determinants of access to HCV testing is needed to improve their engagement in the HCV care cascade. We used data from a cross-sectional survey of people who inject drugs, mainly opioids, to identify factors associated with recent HCV testing. Methods Self-reported data on HCV antibody testing were analyzed for 550 of the 557 PWID enrolled in PrebupIV, a French cross-sectional community-based survey which assessed PWID acceptability of injectable buprenorphine as a treatment. Factors associated with recent (i.e., in the previous six months) HCV antibody testing were identified performing multivariable logistic regression. Results Among the study sample, 79% were men and 31% reported recent HCV antibody testing. Multivariable analysis found that PWID who did not disclose their injection practices to anyone (aOR [95% CI] 0.31 [0.12,0.82], p = 0.018), older PWID (aOR [95% CI] 0.97 [0.95,1.00], p = 0.030) and employed respondents (aOR [95% CI] 0.58 [0.37,0.92], p = 0.019) were all less likely to report recent HCV testing. No association was found between opioid agonist therapy and HCV testing. Conclusions Our findings suggest that non-disclosure of injection practices, employment and age were all barriers to HCV antibody testing. Preventing stigma around injection practices, developing the HCV testing offer in primary care and addiction care services, and training healthcare providers in HCV care management could improve HCV testing and therefore, the HCV care cascade in PWID.https://doi.org/10.1186/s12954-023-00841-7HCV testingPWIDTestingDisclosureStigma |
| spellingShingle | Ilhame Anwar Cécile Donadille Camelia Protopopescu David Michels Joris Herin Adélaïde Pladys Danièle Bader Patrizia Carrieri Perrine Roux Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study Harm Reduction Journal HCV testing PWID Testing Disclosure Stigma |
| title | Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study |
| title_full | Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study |
| title_fullStr | Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study |
| title_full_unstemmed | Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study |
| title_short | Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study |
| title_sort | non disclosure of drug injection practices as a barrier to hcv testing results from the prebupiv community based research study |
| topic | HCV testing PWID Testing Disclosure Stigma |
| url | https://doi.org/10.1186/s12954-023-00841-7 |
| work_keys_str_mv | AT ilhameanwar nondisclosureofdruginjectionpracticesasabarriertohcvtestingresultsfromtheprebupivcommunitybasedresearchstudy AT ceciledonadille nondisclosureofdruginjectionpracticesasabarriertohcvtestingresultsfromtheprebupivcommunitybasedresearchstudy AT cameliaprotopopescu nondisclosureofdruginjectionpracticesasabarriertohcvtestingresultsfromtheprebupivcommunitybasedresearchstudy AT davidmichels nondisclosureofdruginjectionpracticesasabarriertohcvtestingresultsfromtheprebupivcommunitybasedresearchstudy AT jorisherin nondisclosureofdruginjectionpracticesasabarriertohcvtestingresultsfromtheprebupivcommunitybasedresearchstudy AT adelaidepladys nondisclosureofdruginjectionpracticesasabarriertohcvtestingresultsfromtheprebupivcommunitybasedresearchstudy AT danielebader nondisclosureofdruginjectionpracticesasabarriertohcvtestingresultsfromtheprebupivcommunitybasedresearchstudy AT patriziacarrieri nondisclosureofdruginjectionpracticesasabarriertohcvtestingresultsfromtheprebupivcommunitybasedresearchstudy AT perrineroux nondisclosureofdruginjectionpracticesasabarriertohcvtestingresultsfromtheprebupivcommunitybasedresearchstudy |